Skip to main content

Table 3 Adverse event requiring TMP-SMX discontinuation

From: Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study

Adverse event

Low-dose

group (n = 36)

Standard-dose

group (n = 45)

Number of discontinued patients, n (%)

3 (8.3)

13 (28.9)

Details of adverse events

 Fever, n (%)

0 (0.0)

5 (11.1)

 Rash, n (%)

0 (0.0)

6 (13.3)

 Anorexia, n (%)

0 (0.0)

2 (4.4)

 Thrombocytopenia, n (%)

3 (8.3)

6 (13.3)

 Leukocytopenia, n (%)

3 (8.3)

2 (4.4)

 Anemia, n (%)

2 (5.6)

6 (13.3)

 Hyperkalemia, n (%)

1 (2.8)

2 (4.5)

 Hyponatremia, n (%)

2 (5.6)

6 (13.3)

 Increased alanine aminotransferase, n (%)

0 (0.0)

5 (11.1)

 Increased aspartate aminotransferase, n (%)

0 (0.0)

5 (11.1)

  1. The number of patients who discontinued due to adverse events and details of adverse events reported in each group are shown. Thirteen patients in the standard-dose group and three patients in the low-dose group discontinued TMP-SMX due to adverse events. Some patients experienced multiple adverse events
  2. Abbreviation: TMP-SMX trimethoprim-sulfamethoxazole